The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.
S. M. Lavasani
No relevant relationships to disclose
K. I. Pritchard
No relevant relationships to disclose
A. Kiss
No relevant relationships to disclose
S. Verma
Honoraria - GlaxoSmithKline; Roche
F. Wright
No relevant relationships to disclose
J. Boileau
No relevant relationships to disclose
M. E. Trudeau
No relevant relationships to disclose
G. J. Czarnota
No relevant relationships to disclose
R. A. Dent
No relevant relationships to disclose